Incyte

Yahoo Finance • 9 days ago

JPMorgan sees biotech sector at inflection point, resumes coverage on 14 Firms

Investing.com -- JPMorgan has reinstated ratings and price targets on 14 large-cap biotechnology companies, describing the sector as being at a critical “inflection point” as pipeline successes increasingly translate into profitable commer... Full story

Yahoo Finance • 27 days ago

Incyte (INCY) Positioned to Offset Patent Cliff Risks, Analysts Reaffirm Stock Ratings

Incyte Corporation (NASDAQ:INCY) ranks among the most profitable biotech stocks to buy now. On April 15, H.C. Wainwright restated Incyte Corporation (NASDAQ:INCY)’s Buy rating and $135 price target. The firm stated that Incyte’s povorcitin... Full story

Yahoo Finance • 27 days ago

Healthcare earnings impress with 86% beat rate, yet sector lags: Earnings Scorecard

[Magnifying Glass On Top Of Bar Chart] DNY59 Out of 22 S&P 500 healthcare companies that reported results this week, 19 beat earnings expectations and 15 posted year-over-year EPS growth. All 22 companies recorded year-over-year revenue i... Full story

Yahoo Finance • last month

Incyte Corp (INCY) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and Promising ...

This article first appeared on GuruFocus. Total Revenue: $1.27 billion, up 21% year-over-year. Net Sales: $1.1 billion, representing 20% growth year-over-year. Jakafi Sales: $758 million, up 7% year-over-year. Opzelura Sales: $143 million... Full story

Yahoo Finance • last month

Incyte Q1 26 Earnings Conference Call At 8:00 AM ET

(RTTNews) - Incyte Corporation (INCY) will host a conference call at 8:00 AM ET on April 28, 2026, to discuss Q1 26 earnings results. To access the live webcast, log on to https://investor.incyte.com To listen to the call, dial 877-407-3... Full story

Yahoo Finance • last month

Incyte Reports First Quarter 2026 Financial Results and Provides Business Updates

Total revenue of $1.27 billion and total net sales of $1.10 billion in the first quarter of 2026, an increase of 21% and 20% respectively, compared to the first quarter of 2025 Jakafi® (ruxolitinib) net sales of $758 million, an increase... Full story

Yahoo Finance • last month

Incyte Appoints Suketu (Suky) Upadhyay as Chief Financial Officer

WILMINGTON, Del., April 28, 2026--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) announces the appointment of Suketu (Suky) Upadhyay as Executive Vice President and Chief Financial Officer (CFO) effective May 4, 2026. In his new role, Mr. Upadhyay... Full story

Yahoo Finance • last month

Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Regeneron (NASDAQ:REGN) and the best and worst performers in the biotechnology ind... Full story

Yahoo Finance • last month

Adagene (ADAG) Partners With Incyte (INCY) to Evaluate Combination Therapy for Colorectal Cancer

Adagene Inc. (NASDAQ:ADAG) is one of the 10 Unstoppable Stocks That Could Double Your Money. Adagene Inc. (NASDAQ:ADAG) is one of the unstoppable stocks that could double your money. On April 2, Adagene announced a clinical collaboration... Full story

Yahoo Finance • 2 months ago

Notable healthcare headlines for the week: Apellis, Centessa, and UnitedHealth in focus

Wall Street’s major market averages ended mixed on Thursday as markets assessed President Donald Trump’s address to the nation and the latest developments in the Middle East conflict. The tech-focused Nasdaq Composite finished +0.1%. At t... Full story

Yahoo Finance • 2 months ago

Adagene Announces Clinical Collaboration with Incyte to Evaluate Muzastotug (ADG126) in Combination with Incyte’s TGFßR2xPD-1 Bispecific Antibody (INCA33890) in Patients with Microsatellite Stable Colorectal Cancer (MSS CRC)

Phase 1 study of INCA33890 and muzastotug expected to begin in 2026 in 3L MSS CRC patientswith and without liver metastases Study will be sponsored and conducted by Incyte; Adagene to provide clinical supply of muzastotug Collaboration p... Full story

Yahoo Finance • 2 months ago

5 Biotechs That Big Pharma Could Snap Up as Oncology M&A Heats Up

Quick Read Incyte (INCY) posted FY2025 revenue of $5.14B (+21.2% YoY) with 14 pivotal trials underway across KRASG12D and CDK2 inhibition, while Alnylam (ALNY) achieved first full-year GAAP profitability with FY2025 revenue surging 65.2%... Full story

Yahoo Finance • 2 months ago

Renal Cell Carcinoma Market Report 2026-2030 & 2035: Increasing Immunotherapy and Precision Oncology Programs Drives Market Expansion, Reaching USD 6.09 Billion by 2030

Dublin, April 01, 2026 (GLOBE NEWSWIRE) -- The "Renal Cell Carcinoma Market Report 2026" has been added to ResearchAndMarkets.com's offering. The report provides a comprehensive analysis, depicting global market size, regional shares,... Full story

Yahoo Finance • 2 months ago

Recurrent Head and Neck Cancer Squamous Cell Carcinoma Markets and Competition Outlook 2026-2030: Personalized Medicine Drives Revenue Growth, Reaching $4.61 Billion by 2030

Dublin, March 30, 2026 (GLOBE NEWSWIRE) -- The "Recurrent Head and Neck Cancer Squamous Cell Carcinoma Market Report 2026" has been added to ResearchAndMarkets.com's offering. The report offers comprehensive insights on market size, reg... Full story

Yahoo Finance • 2 months ago

Qualcomm, Adobe downgraded: Wall Street's top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: Clear Street upgraded Circle Internet(... Full story

Yahoo Finance • 2 months ago

Here Are Monday’s Top Wall Street Analyst Research Calls: Alnylam Pharmaceuticals, Circle Internet, Fifth Third Bancorp, Intuit, ServiceNow, Qualcomm, Trade Desk, and More

Quick Read Stocks closed lower once again on Friday, handing investors their third consecutive week of losses. The “Buy the Dip” investors were rarely wrong using that tactic over the last 3 years, but have been scorched recently While it... Full story

Yahoo Finance • 3 months ago

2 Value Stocks to Consider Right Now and 1 We Ignore

Value investing has produced some of the world’s most famous investing billionaires, including Warren Buffett, David Einhorn, and Seth Klarman, who built their fortunes by purchasing wonderful businesses at reasonable prices. But these hid... Full story

Yahoo Finance • 3 months ago

Incyte (INCY): Buy, Sell, or Hold Post Q4 Earnings?

Over the past six months, Incyte has been a great trade, beating the S&P 500 by 8.1%. Its stock price has climbed to $95.88, representing a healthy 11.3% increase. This was partly due to its solid quarterly results, and the run-up might ha... Full story

Yahoo Finance • 3 months ago

Incyte fails to win FDA label expansion for cancer therapy due to issues at Novo plant

[FDA headquarters in Washington DC.] JHVEPhoto The U.S. Food and Drug Administration has declined to approve an additional indication for Zynyz, a cancer therapy developed by Incyte (INCY [https://seekingalpha.com/symbol/INCY]) and MacroG... Full story

Yahoo Finance • 3 months ago

Assessing Incyte (INCY) Valuation After Recent Share Price Weakness And Mixed Fair Value Signals

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Incyte (INCY) has drawn fresh attention after recent trading left the shares with a 1-day return... Full story